A Pilot Study of Repetitive Transcranial Magnetic Stimulation for Treatment of Methamphetamine Use Disorders
NCT ID: NCT04883021
Last Updated: 2021-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2020-08-01
2021-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Transcranial magnetic stimulation (TMS) using either high frequency stimulation or intermittent theta burst stimulation is a non-invasive brain stimulation technique that effectively treats major depressive disorder and is considered safe, well-tolerated, and potent. TMS has increasingly been studied to treat addiction. The dorsolateral prefrontal cortex (DLPFC), a brain region implicated in regulatory processes related to executive function, emotion, motivation, and craving, is a common target for TMS. DLPFC stimulation using high frequency repetitive TMS has reduced craving in many studies of addictive disorders, including cocaine and MAUD. In addition to the DLPFC target, emerging evidence indicates that continuous theta burst stimulation (cTBS) delivered to the medial prefontal cortex (MPFC) during drug cue activation reduced craving and related brain activity in cocaine users. Despite these encouraging findings, no trials have reported on the efficacy of TMS for reducing MA use or preventing relapse. Clinical research on TMS for MAUD is sparse in the United States, and the limited studies of TMS in MAUD have been in experimental or closed treatment settings where effects on actual MA use are difficult to evaluate.
We are proposing a pilot study in 8 people with MAUD engaged in psychosocial treatment to explore the effects and tolerability of a four-week treatment protocol combining intermittent theta burst stimulation of the DLPFC with cTBS targeting the MPFC (dual-target TMS). We expect that this combined approach will enhance executive function and inhibitory control and reduce craving through separate but related mechanisms. We will evaluate clinical outcomes including symptoms and substance use, changes in functional connectivity measured via MRI and their relationship to treatment response, and changes in impulsivity as measured by performance on a response inhibition task. This project has the following specific aims:
Aim 1: Characterize changes in craving, depressive symptoms, anxiety symptoms, sleep quality, quality of life, and MA or other stimulant use over four weeks of dual-target TMS and eight weeks of subsequent follow-up.
Aim 2: Estimate changes in functional connectivity in the brain and response inhibition and selective attention in people with MAUD after four weeks of dual-target TMS.
Aim 3: Evaluate retention in the study to establish feasibility and tolerability of the protocol.
Aim 4: Compare retention in psychosocial treatment and positive urine drug screens in study participants compared to matched historical controls.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dual Target Theta Burst Stimulation
The TMS intervention is open-label dual-target theta burst stimulation delivered in sequential fashion to the DLPFC and the MPFC.
Dual Target Theta Burst Stimulation
TMS treatment will be provided daily for 5 days, then daily for 5 days in week 2, and three times per week (Monday, Wednesday, Friday) in weeks 3 and 4.
Treatment targeting will occur at the Beam F3 and FP1 scalp regions as defined by the 10-20 EEG system and previous publications. A Magventure MagPro X100 figure-8 coil with theta burst capabilities will be used to deliver the stimulus, including intermittent theta burst stimulation to the DLPFC (2 seconds of 50-Hz triplets delivered at 5 Hz, 8 seconds intertrain interval, 600 total pulses) and continuous theta burst to the MPFC (continuous 50-Hz stimulation triplets, 600 pulses). Stimulation will be delivered at 110% of the resting motor threshold.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dual Target Theta Burst Stimulation
TMS treatment will be provided daily for 5 days, then daily for 5 days in week 2, and three times per week (Monday, Wednesday, Friday) in weeks 3 and 4.
Treatment targeting will occur at the Beam F3 and FP1 scalp regions as defined by the 10-20 EEG system and previous publications. A Magventure MagPro X100 figure-8 coil with theta burst capabilities will be used to deliver the stimulus, including intermittent theta burst stimulation to the DLPFC (2 seconds of 50-Hz triplets delivered at 5 Hz, 8 seconds intertrain interval, 600 total pulses) and continuous theta burst to the MPFC (continuous 50-Hz stimulation triplets, 600 pulses). Stimulation will be delivered at 110% of the resting motor threshold.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Is engaged in psychosocial treatment or articulates a plan to engage in psychosocial treatment for methamphetamine use disorder during the study period
* Age 18 to 60 years
* Able to consent for treatment and research participation
* English-speaking
Exclusion Criteria
* Patients that are excluded during TMS assessment including: patients with epilepsy or seizure disorder, patients with implanted ferromagnetic equipment in their face or skull near the stimulation target.
* Current medical treatment with clozapine, bupropion, or stimulants.
* Current diagnosis of bipolar disorder, schizoaffective disorder, schizophrenia, or any other psychotic disorder.
* Legal or mental incompetency, or inability to consent to study.
* Unstable medical illness.
* Current diagnosis of neurological disorder or neurocognitive disorder.
* Prior neurosurgical procedure.
* History of seizure.
* History of ECT treatment within the past three months.
* History of any previous TMS treatment.
* Inability to complete the protocol, namely, inability to independently attend all study visits and TMS sessions on time.
* Prisoner
* Implanted device including pacemaker, coronary stent, defibrillator, or neurostimulation device that is not MRI-compatible
* Metal in body including bullets, shrapnel, metal slivers
* Claustrophobia
* Uncontrolled high blood pressure
* Atrial fibrillation
* Significant heart disease
* Hemodynamic instability
* Kidney disease
* Pregnant (MRI contraindicated during pregnancy)
* Unable to understand English (behavioral tests of impulsivity are only in English)
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Iowa
OTHER
University of Utah
OTHER
University of New Mexico
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of New Mexico Health Sciences Center
Albuquerque, New Mexico, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UNM HRRC# 20-077
Identifier Type: -
Identifier Source: org_study_id